As treatment paradigms continue to evolve—particularly with the integration of FLT3 inhibitors—the prognostic significance of co-mutations in FLT3-mutant AML will undoubtedly continue to shift, underscoring the need for dynamic, genotype-informed therapeutic strategies. The gene discussed is FLT3; the disease is acute myeloid leukemia.